GMED vs. DXCM, STE, PODD, HOLX, BAX, MASI, TFX, ITGR, ATEC, and ATRC
Should you be buying Globus Medical stock or one of its competitors? The main competitors of Globus Medical include DexCom (DXCM), STERIS (STE), Insulet (PODD), Hologic (HOLX), Baxter International (BAX), Masimo (MASI), Teleflex (TFX), Integer (ITGR), Alphatec (ATEC), and AtriCure (ATRC). These companies are all part of the "health care equipment" industry.
Globus Medical vs. Its Competitors
DexCom (NASDAQ:DXCM) and Globus Medical (NYSE:GMED) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.
DexCom currently has a consensus price target of $97.42, indicating a potential upside of 42.28%. Globus Medical has a consensus price target of $87.64, indicating a potential upside of 46.61%. Given Globus Medical's higher possible upside, analysts plainly believe Globus Medical is more favorable than DexCom.
97.8% of DexCom shares are held by institutional investors. Comparatively, 95.2% of Globus Medical shares are held by institutional investors. 0.3% of DexCom shares are held by company insiders. Comparatively, 18.5% of Globus Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
In the previous week, DexCom had 11 more articles in the media than Globus Medical. MarketBeat recorded 18 mentions for DexCom and 7 mentions for Globus Medical. Globus Medical's average media sentiment score of 0.83 beat DexCom's score of 0.69 indicating that Globus Medical is being referred to more favorably in the news media.
DexCom has higher revenue and earnings than Globus Medical. Globus Medical is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.
DexCom has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500. Comparatively, Globus Medical has a beta of 1.12, indicating that its stock price is 12% more volatile than the S&P 500.
Globus Medical has a net margin of 13.58% compared to DexCom's net margin of 13.29%. DexCom's return on equity of 30.41% beat Globus Medical's return on equity.
Summary
DexCom beats Globus Medical on 12 of the 17 factors compared between the two stocks.
Get Globus Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for GMED and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding GMED and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Globus Medical Competitors List
Related Companies and Tools
This page (NYSE:GMED) was last updated on 10/9/2025 by MarketBeat.com Staff
